Literature DB >> 11096691

Parkinson's Disease: The Proper Use of Dopamine Receptor Agonists.

.   

Abstract

Although dopamine receptor agonists are not simple to use, they are assuming increased importance in the treatment of early and advanced symptoms of Parkinson's disease (PD). The new agonists, pramipexole and ropinirole, are generally adequate without levodopa for early symptoms and carry the hope for a more acceptable profile of long-term side effects. In the patient with advanced disease, all four dopamine agonists significantly augment the response to levodopa, which reduces the problems of motor fluctuations and drug-related dyskinesia. Understanding the common pitfalls when prescribing these drugs will facilitate their safety and efficacy.

Entities:  

Year:  1999        PMID: 11096691     DOI: 10.1007/s11940-999-0028-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  15 in total

1.  Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study.

Authors:  A Lieberman; A Ranhosky; D Korts
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

2.  Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.

Authors:  C H Adler; K D Sethi; R A Hauser; T L Davis; J P Hammerstad; J Bertoni; R L Taylor; J Sanchez-Ramos; C F O'Brien
Journal:  Neurology       Date:  1997-08       Impact factor: 9.910

Review 3.  Levodopa: is toxicity a myth?

Authors:  Y Agid
Journal:  Neurology       Date:  1998-04       Impact factor: 9.910

Review 4.  The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Authors:  T N Chase
Journal:  Drugs       Date:  1998       Impact factor: 9.546

5.  Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.

Authors:  C W Olanow; M J Alberts
Journal:  Adv Neurol       Date:  1987

6.  Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  1997-07-09       Impact factor: 56.272

Review 7.  New pharmacotherapy for Parkinson's disease.

Authors:  M D Gottwald; J L Bainbridge; G A Dowling; M J Aminoff; B K Alldredge
Journal:  Ann Pharmacother       Date:  1997-10       Impact factor: 3.154

8.  Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.

Authors:  A N Lieberman; A Neophytides; M Leibowitz; G Gopinathan; V Pact; R Walker; A Goodgold; M Goldstein
Journal:  Adv Neurol       Date:  1983

9.  Treatment of parkinson's disease with bromocriptine.

Authors:  A Lieberman; M Kupersmith; E Estey; M Goldstein
Journal:  N Engl J Med       Date:  1976-12-16       Impact factor: 91.245

10.  Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.

Authors:  C G Goetz; C M Tanner; R H Glantz; H L Klawans
Journal:  Neurology       Date:  1985-05       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.